Oculis HoldingOCS
Recorded

Oculis Holding Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration32 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Annabel SamimyManaging Director of Biopharmaceuticals

All right. Good afternoon, everyone, and welcome to the Oculis presentation. We are pleased to have Riad Sherif with us today, Chief Executive Officer of Oculis, and we have Sylvia Cheung taking pictures in the back, CFO. Thank you for joining us today. Oculis is a diversified ophthalmology company that is transitioning to neuro-ophthalmology, depending on how things come out with licaminlimab, which I said very well. Thank you. Yes. Ryad, maybe you can just give us an overview first, and then we can go into questions.

Riad SherifCEO

Yeah. Thank you, Annabelle, and thank you, Stifel, for a well-organized meeting. As you said, Oculis is a neuro-ophthalmology company.

Riad SherifCEO

Yeah, that is it. Or neuroprotection company.

Riad SherifCEO

In fact, the first neuroprotection company with clinical data. At the same time, we have an upcoming readout in ophthalmology with the product which is called licaminlimab in a subset of population of dry eye. As you know, dry eye is a very, I would say, heterogeneous disease, and we are focusing on a subset of population which is called TNFR1, and this result is coming in upcoming weeks.

Riad SherifCEO

In neuro-ophthalmology and neuro, we have a candidate which is called privosegtor. Privosegtor was tested in acute optic neuritis or optic neuritis, which is an inflammation of the optic nerve. In more than 60% of the cases, it's an exacerbation of multiple sclerosis, and it comes with pain and loss of vision. We are really talking about young population, young patient. The average age is 32 years. I really speak about it because I saw it. It's really like the typical patient is a young mother who lose her vision. It's devastating for the person. In general, two-thirds of these patients recover BCVA, but not LCVA. Therefore, you end up at 32 years not being able to use a screen, not being able to drive or do multiple things in life. This is after first exacerbation. If you have more, of course, it's worse.

Riad SherifCEO

Therefore, in our trial, which is called ACUITY, which was a phase II, we showed that with privosegtor, that we were able to improve vision by 18 letters, which was LCVA. We preserved the structure of the retina, and we preserved really the neuronal structure of the retina, which is called retinal ganglion cells, or GCIPL. We reduced the axonal damage, and it was measured with the neurofilament, and we reduced astrocyte activation or neuroinflammation by reducing the GFAP. An amazing data set, because everything going into the same direction. Our product was granted Breakthrough Therapy designation in the U.S., PRIME in Europe, and now privosegtor is in phase III.

Annabel SamimyManaging Director of Biopharmaceuticals

Great. Let's continue with privosegtor.

Annabel SamimyManaging Director of Biopharmaceuticals

Okay. Or do you want to start with licaminlimab?

Annabel SamimyManaging Director of Biopharmaceuticals

You decide. Okay. Let's get licaminlimab out of the way, because that's going to be the next data point you see.

Annabel SamimyManaging Director of Biopharmaceuticals

That's going to be the first of possibly four, maybe up to four trials for dry eye disease. So, what does success look like to you in this trial?

Riad SherifCEO

The first layer of success is the positive study.

Riad SherifCEO

Okay. The second layer is doing better than the competition.

Riad SherifCEO

I would say the question is really why we are going with the TNF in dry eye, and then after, why precision medicine? Why not doing a product for everyone? There are millions of patients. The first why TNF is because inflammation is the core component of dry. Inflammation sustain the pain and the irritation and the redness and the disease itself. Therefore, tackling inflammation makes this product potentially one of the first really disease-modifying drug in dry eye. Therefore, it is very relevant. Now, why going to precision medicine? Dry eye, as you know, there is huge variability in patients, and we end up in situations where phase IIIs are complicated because of variability of patients.

Riad SherifCEO

We end up also commercially having a very unsatisfied population, where in general, when you do surveys, typically 87% of patients are not happy with their drug. In fact, when you see the renewal of prescription at month 6, 85%-90% of patients stop their drug because they are not happy. Therefore, what we did, based on our phase II, we really asked ourself, "Okay, if we go to the high responders, can we identify these high responders ahead of time?" We were lucky to identify a biomarker which really allows us actually to, in pre-specified manner, to identify this biomarker and know who will respond and who will not respond.

Riad SherifCEO

We tested this hypothesis in a previous trial, which was called RELIEF, and the product in between the two last trials showed that in TNFR1 population, we were able to deliver five times better improvement in signs and seven times better improvement in symptoms. Therefore, we met with FDA, we shared our data, and FDA agreed for us to go to TNFR1 population. In fact, we are enriching the phase III with the TNFR1. Two-thirds of the patients are TNFR1 in PREDICT-1, which is the first symptom trial. Primary endpoint will be mean improvement in TNFR1 patient. Secondary endpoint will be mean improvement in all-comers. The last secondary endpoint, which is really important, will be responders. How many patients gain more than 20 points, or how many patients improve more than 20 points? This endpoint is really important because many times we focus on mean.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day